Table 1 Trial endpoints
Primary endpoint | Proportions of patients that achieve return of spontaneous circulation with a duration of at least 20 min |
|---|---|
Secondary endpoints | The proportion of patients surviving to 30 days with good neurological status, defined as a modified Rankin scale score of 0–3 |
Difference in end-tidal CO2 measurements in the control group and the intervention group after aortic occlusion | |
Change in blood pressures after aortic occlusion | |
Left ventricular ejection fraction (LVEF) measured by echocardiography | |
Exploratory endpoints | All-cause mortality 1 year after randomisation |
Difference in organ function, using the Acute Kidney Injury Network (AKIN) classification, liver function blood tests, and others | |
Incidence of all adverse events |